Abstract
Introduction Targeted temperature management (TTM) has been associated with greater likelihood of neurological recovery among comatose survivors of cardiac arrest. However, the efficacy of TTM is not consistently observed, possibly due to heterogeneity of therapeutic response. The aim of this study is to determine if models leveraging multi-modal data available in the first 12 hours after ICU admission (hyperacute phase) can predict short-term outcome after TTM.
Methods Adult patients receiving TTM after cardiac arrest were selected from a multicenter ICU database. Predictive features were extracted from clinical, physiologic, and laboratory data available in the hyperacute phase. Primary endpoints were survival and favorable neurological outcome, determined as the ability to follow commands (motor Glasgow Coma Scale [mGCS] of 6) upon discharge. Three machine learning (ML) algorithms were trained: generalized linear models (GLM), random forest (RF), and gradient boosting (XG). Models with optimal features from forward selection were 10-fold cross-validated and resampled 10 times.
Results Data were available on 310 cardiac arrest patients who received TTM, of whom 183 survived and 123 had favorable neurological outcome. The GLM performed best, with an area under the receiver operating characteristic curve (AUROC) of 0.86 ± 0.04, sensitivity 0.75 ± 0.09, and specificity 0.77 ± 0.07 for the prediction of survival and an AUROC of 0.85 ± 0.03, sensitivity 0.71 ± 0.10, and specificity 0.80 ± 0.12 for the prediction of favorable neurological outcome. Features most predictive of both endpoints included lower serum chloride concentration, higher serum pH, and greater neutrophil counts.
Conclusion In patients receiving TTM after cardiac arrest, short-term outcomes can be accurately discriminated using ML applied to data routinely collected in the first 12 hours after ICU admission. With validation, hyperacute prediction could enable personalized approach to clinical decision-making in the post-cardiac arrest setting.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
IRB of Johns Hopkins University gave ethical approval for this work.
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
jhsu37{at}jhu.edu
hankim{at}jhu.edu
kgong1{at}jhu.edu
tazad1{at}jhmi.edu
rstevens{at}jhmi.edu
Data Availability
All data produced in the present study are available upon reasonable request to the authors.
